AGP Executive Report
Last update: 7 hours agoVaccine Progress: Vaxcyte says its Phase 3 VAX-31 pneumococcal vaccine met primary endpoints, with immune responses across 31 strains and a safety profile similar to existing vaccines. Drug Development: CSL and Alentis struck a deal worth up to $1.55 billion to develop a kidney and liver disease drug; Genentech licensed Alector’s experimental Parkinson’s therapy in a deal worth up to $1.27 billion. Market Access: Celltrion has launched Omlyclo in the US, the first interchangeable biosimilar to Xolair. Infectious Disease: Florida reported 252 locally acquired dengue cases by late September, far above recent years. India is also launching youth-led TB awareness teams in 55 districts, alongside an AI-powered public information chatbot. Earlier Intervention: Experts are urging primary care to play a larger role in liver disease as cases linked to obesity and alcohol rise.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
